Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

10/26/2025

Janusmed sex and gender

Janusmed sex and gender – Alprazolam

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
B B
B B

Alprazolam testing environment

Alprazolam

Class : B

Show all info

Print

Contact us

  1. Greenblatt DJ, Wright CE. Clinical pharmacokinetics of alprazolam Therapeutic implications. Clin Pharmacokinet. 1993;24:453-71.

  2. Arbanas G, Arbanas D, Dujam K. Adverse effects of benzodiazepines in psychiatric outpatients. Psychiatr Danub. 2009;21:103-7.

  3. Kirkwood C, Moore A, Hayes P, DeVane CL, Pelonero A. Influence of menstrual cycle and gender on alprazolam pharmacokinetics. Clin Pharmacol Ther. 1991;50:404-9.

  4. Johnell K, Fastbom J. The use of benzodiazpines and related drugs amongst older people in Sweden: associated factors and concomitant use of other psychotropics. Int J Geriatr Psychiatry. 2009;24:731-8.

  5. Kristjánsson F, Thorsteinsson SB. Disposition of alprazolam in human volunteers Differences between genders. Acta Pharm Nord. 1991;3:249-50.

  6. Greenblatt DJ, Divoll M, Abernethy DR, Moschitto LJ, Smith RB, Shader RI. Alprazolam kinetics in the elderly Relation to antipyrine disposition. Arch Gen Psychiatry. 1983;40:287-90.

  7. Hossain M, Wright E, Baweja R, Ludden T, Miller R. Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam. Pharm Res. 1997;14:309-15.

  8. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - NIRAVAM (alprazolam). Food and Drug Administration [www]. [updated 2005-01-19, cited 2015-10-15].

  9. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - XANAX XR (alprazolam). Food and Drug Administration [www]. [updated 2003-01-17, cited 2015-10-15].

  10. Stoehr GP, Kroboth PD, Juhl RP, Wender DB, Phillips JP, Smith RB. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin Pharmacol Ther. 1984;36:683-90.

  11. Scavone JM, Greenblatt DJ, Locniskar A, Shader RI. Alprazolam pharmacokinetics in women on low-dose oral contraceptives. J Clin Pharmacol. 1988;28:454-7.

  12. Sfinx Interaktioner. Stockholm: Stockholm County Council. 2015 [cited 2015-10-05.]

  13. Pomara N, Willoughby LM, Ritchie JC, Sidtis JJ, Greenblatt DJ, Nemeroff CB. Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance. Psychopharmacology (Berl). 2005;182:414-9.

  14. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.]

  1. Greenblatt DJ, Wright CE. Clinical pharmacokinetics of alprazolam Therapeutic implications. Clin Pharmacokinet. 1993;24:453-71.
  2. Arbanas G, Arbanas D, Dujam K. Adverse effects of benzodiazepines in psychiatric outpatients. Psychiatr Danub. 2009;21:103-7.
  3. Kirkwood C, Moore A, Hayes P, DeVane CL, Pelonero A. Influence of menstrual cycle and gender on alprazolam pharmacokinetics. Clin Pharmacol Ther. 1991;50:404-9.
  4. Johnell K, Fastbom J. The use of benzodiazpines and related drugs amongst older people in Sweden: associated factors and concomitant use of other psychotropics. Int J Geriatr Psychiatry. 2009;24:731-8.
  5. Kristjánsson F, Thorsteinsson SB. Disposition of alprazolam in human volunteers Differences between genders. Acta Pharm Nord. 1991;3:249-50.
  6. Greenblatt DJ, Divoll M, Abernethy DR, Moschitto LJ, Smith RB, Shader RI. Alprazolam kinetics in the elderly Relation to antipyrine disposition. Arch Gen Psychiatry. 1983;40:287-90.
  7. Hossain M, Wright E, Baweja R, Ludden T, Miller R. Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam. Pharm Res. 1997;14:309-15.
  8. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - NIRAVAM (alprazolam). Food and Drug Administration [www]. [updated 2005-01-19, cited 2015-10-15].
  9. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - XANAX XR (alprazolam). Food and Drug Administration [www]. [updated 2003-01-17, cited 2015-10-15].
  10. Stoehr GP, Kroboth PD, Juhl RP, Wender DB, Phillips JP, Smith RB. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin Pharmacol Ther. 1984;36:683-90.
  11. Scavone JM, Greenblatt DJ, Locniskar A, Shader RI. Alprazolam pharmacokinetics in women on low-dose oral contraceptives. J Clin Pharmacol. 1988;28:454-7.
  12. Sfinx Interaktioner. Stockholm: Stockholm County Council. 2015 [cited 2015-10-05.]
  13. Pomara N, Willoughby LM, Ritchie JC, Sidtis JJ, Greenblatt DJ, Nemeroff CB. Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance. Psychopharmacology (Berl). 2005;182:414-9.
  14. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.]